Purple Biotech Future Growth
Future criteria checks 0/6
Purple Biotech is forecast to grow revenue at 100.3% per annum.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Pharmaceuticals earnings growth | 16.2% |
Revenue growth rate | 100.3% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 19 Sep 2024 |
Recent future growth updates
No updates
Recent updates
We're A Little Worried About Purple Biotech's (TLV:PPBT) Cash Burn Rate
Mar 07Can Purple Biotech (TLV:PPBT) Afford To Invest In Growth?
Oct 30Will Purple Biotech (TLV:PPBT) Spend Its Cash Wisely?
Jul 17Here's Why We're Watching Purple Biotech's (TLV:PPBT) Cash Burn Situation
Mar 13Is Purple Biotech (TLV:PPBT) In A Good Position To Deliver On Growth Plans?
Nov 27Is Purple Biotech (TLV:PPBT) In A Good Position To Deliver On Growth Plans?
Jul 21Purple Biotech (TLV:PPBT) Is In A Good Position To Deliver On Growth Plans
Mar 25Companies Like Purple Biotech (TLV:PPBT) Are In A Position To Invest In Growth
Dec 09Purple Biotech (TLV:PPBT) Is In A Good Position To Deliver On Growth Plans
May 28We Think Purple Biotech (TLV:PPBT) Can Afford To Drive Business Growth
Feb 11If You Had Bought Purple Biotech's (TLV:KTOV) Shares Five Years Ago You Would Be Down 90%
Dec 21Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | N/A | N/A | -15 | N/A | 1 |
12/31/2025 | N/A | N/A | -7 | N/A | 1 |
12/31/2024 | N/A | N/A | -2 | N/A | 1 |
9/30/2024 | N/A | -12 | -17 | -17 | N/A |
6/30/2024 | N/A | -16 | -18 | -18 | N/A |
3/31/2024 | N/A | -19 | -19 | -19 | N/A |
12/31/2023 | N/A | -20 | -20 | -20 | N/A |
9/30/2023 | N/A | -21 | -19 | -19 | N/A |
6/30/2023 | N/A | -21 | -19 | -19 | N/A |
3/31/2023 | N/A | -19 | -18 | -18 | N/A |
12/31/2022 | N/A | -22 | -17 | -17 | N/A |
9/30/2022 | N/A | -20 | -17 | -16 | N/A |
6/30/2022 | N/A | -19 | -16 | -16 | N/A |
3/31/2022 | N/A | -19 | -17 | -17 | N/A |
12/31/2021 | N/A | -18 | -15 | -15 | N/A |
9/30/2021 | N/A | -13 | N/A | N/A | N/A |
6/30/2021 | -1 | -11 | -16 | -16 | N/A |
3/31/2021 | 1 | -21 | N/A | N/A | N/A |
12/31/2020 | N/A | -29 | -12 | -12 | N/A |
9/30/2020 | 1 | -30 | -10 | -10 | N/A |
6/30/2020 | 1 | -31 | -8 | -8 | N/A |
3/31/2020 | 1 | -18 | -7 | -7 | N/A |
12/31/2019 | N/A | -5 | -6 | -6 | N/A |
9/30/2019 | 1 | -4 | -6 | -6 | N/A |
6/30/2019 | 1 | -3 | -7 | -7 | N/A |
3/31/2019 | 1 | -4 | -8 | -8 | N/A |
12/31/2018 | 1 | -5 | -8 | -8 | N/A |
9/30/2018 | 1 | -8 | -8 | -8 | N/A |
6/30/2018 | 1 | -11 | N/A | -7 | N/A |
3/31/2018 | 1 | -12 | N/A | -8 | N/A |
12/31/2017 | 0 | -12 | N/A | -9 | N/A |
9/30/2017 | 0 | -14 | N/A | -9 | N/A |
6/30/2017 | N/A | -15 | N/A | -9 | N/A |
3/31/2017 | N/A | -14 | N/A | -7 | N/A |
12/31/2016 | N/A | -12 | N/A | -6 | N/A |
9/30/2016 | N/A | -9 | N/A | -5 | N/A |
6/30/2016 | N/A | -6 | N/A | -4 | N/A |
3/31/2016 | N/A | -5 | N/A | -4 | N/A |
12/31/2015 | N/A | -4 | N/A | -3 | N/A |
9/30/2015 | N/A | -4 | N/A | -3 | N/A |
6/30/2015 | N/A | -4 | N/A | -3 | N/A |
3/31/2015 | N/A | -5 | N/A | -3 | N/A |
12/31/2014 | N/A | -5 | N/A | -5 | N/A |
9/30/2014 | N/A | -5 | N/A | -4 | N/A |
6/30/2014 | N/A | -6 | N/A | -3 | N/A |
3/31/2014 | N/A | -4 | N/A | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if PPBT's forecast earnings growth is above the savings rate (2.5%).
Earnings vs Market: Insufficient data to determine if PPBT's earnings are forecast to grow faster than the IL market
High Growth Earnings: Insufficient data to determine if PPBT's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: PPBT is forecast to have no revenue next year.
High Growth Revenue: PPBT is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PPBT's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/29 09:29 |
End of Day Share Price | 2024/12/26 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Purple Biotech Ltd is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Emily Bodnar | H.C. Wainwright & Co. |
Raghuram Selvaraju | Rodman & Renshaw, LLC |